Prostanoid Receptors

Items 1-50 of 55

per page
Set Descending Direction
Catalog No.
Product Name
Product Information
Product Citation
  1. DP1 inhibitor

    Laropiprant is used in combination with niacin to reduce blood cholesterol. Laropiprant acts as a DP1 antagonist, reducing the vasodilation.
  2. EP4 receptor antagonist

    MK-2894 is a highly potent and selective second generation EP4 antagonist.
  3. EP4 antagonist

    MK-2894 sodium salt is a highly potent and selective second generation EP4 antagonist.
  4. EP4 antagonist

    ONO-AE3-208 is an EP4 antagonist, and suppresses cell invasion, migration, and metastasis of prostate cancer.
  5. Thromboxane A2 synthesis inhibitor

    Ozagrel is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.
  6. Prostaglandin D2 receptor CRTH2 antagonist

    CAY10471 Racemate (TM30089 Racemate) is a potent and highly selective prostaglandin D2 receptor CRTH2 antagonist.
  7. Prostaglandin E1 (PGE1) is the theoretical cyclooxygenase metabolite of dihomo-γ-linolenic acid (DGLA), but it is virtually undetectable in the plasma of normal humans or other animals. The IC50 of PGE1 for the inhibition of ADP-induced human platelet aggregation is 40 nM.
  8. Prostaglandin E2 is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.
  9. EP2 Receptor antagonist

    PF-04418948 is a potent and selective prostaglandin EP2 receptor antagonist with IC50 of 16 nM. Phase 1.
  10. prostaglandin F2α (PGF2α) analogue

    (+)-Cloprostenol is a prostaglandin F2α (PGF2α) analogue, and shows selective agonistic activity at the prostaglandin receptor.
  11. MK-447 is a free radical scavenger, also a nonsteroidal antiinflammatory agent, and enhances the formation of the endoperoxide, PGH2, and other prostaglandins.
  12. prostaglandin (PG) antagonist

    Aligeron is a non-selective prostaglandin (PG) antagonist, and has vasodilatory properties.
  13. prostanoid DP-receptor (DP1) agonist

    BW 245C is a prostanoid DP-receptor (DP1) agonist, used to treat stroke.
  14. prostaglandin F2α analog

    Cloprostenol is a synthetic analog of prostaglandin F2α (PGF2α). It is 200 times and 100 times more potent than PGF2α in terminating pregnancy in hamsters and rats, respectively, without the side effects associated with PGF2α.
  15. dual antagonist of TP/DP2

    BAY-u 3405 is an approved human medication for the treatment of allergic rhinitis that has documented activity as an antagonist of the thromboxane receptor (TP receptor).
  16. prostacyclin receptor agonist

    NS-304 is a selective prostacyclin IP1 receptor agonist (Ki values are 260 and 2100 nM and for human and rat IP receptors, and >10 μM for EP1-4, DP, FP, and TP receptors).
  17. Prostanoid activator

    Saikosaponin B2 is a saponin activator.
  18. EP4 receptor antagonist

    GW627368 is a novel, potent and selective competitive antagonist of prostanoid EP4 receptor(Ki= 100 nM) with additional human TP receptor affinity(Ki= 150 nM).
  19. EP4 receptor antagonist

    MF498 is a novel and selective E prostanoid receptor 4 (EP4 receptor) antagonist, displayed strong binding affinity for the EP4 receptor with Ki of 0.7 nM,
  20. EP2 Agonist

    C-544326 is a potent and selective prostaglandin E2 receptor agonist with EC50 value of 2.8 nM.
  21. prostaglandin EP4 receptor antagonist

    Grapiprant is a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties.
  22. Prostaglandin E2 receptor antagonist

    TG6-10-1 is a potent and selective antagonist for the prostaglandin E2 receptor subtype EP2.
  23. Prostaglandin F2α is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient.
  24. DP1 receptor antagonist

    Asapiprant, also known as S-555739, is a the potent and selective DP1 receptor antagonist. Asapiprant exhibited high affinity and selectivity for the DP1 receptor.
  25. EP1 receptor antagonist

    GSK-269984A is a novel EP1 receptor antagonist.
  26. IP (prostacyclin) receptor antagonist

    RO-1138452 is a potent and selective IP (prostacyclin) receptor antagonist with high affinity for IP receptors.
  27. CRTh2 receptor antagonist

    Fevipiprant, also known as NVP-QAW039 or QAW039, is an oral active and potent CRTh2 receptor antagonist and potentially useful for asthma treatment.
  28. Misoprostol is a medication used to start labor, cause an abortion, prevent and treat stomach ulcers, and treat postpartum bleeding due to poor contraction of the uterus. For abortions it is often used with mifepristone or methotrexate. By itself effectiveness for this purpose is between 66% and 90%.
  29. prostaglandin analogue

    Tafluprost, also known as MK2452 and AFP-168, is a prostaglandin analogue used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.
  30. Prostaglandin Receptor inhibitor

    Benorilate, also known as Win-11450, is an ester of aspirin and paracetamol with analgesic, antipyretic, and anti-inflammatory activity used in the treatment of rheumatoid diseases. Benorilate has less severe side effects than aspirin.
  31. Prostaglandin Receptor inhibitor

    Dinoprost Tromethamine, also known as Dinoprost Trometamol, is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient.
  32. selective IP receptor agonist

    MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.
  33. EP4 agonist

    KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration.
  34. EP4 receptor antagonist

    BAY-1316957 is a highly potent and selective EP4 receptor antagonist with an IC50 of 15.3 nM. Good oral bioavailability.
  35. PGF2α receptor antagonist

    OBE022 is an oral and selective prostaglandin F2α (PGF2α) receptor antagonist, with Kis of 1 nM, 26 nM for human and rat FP receptors, respectively.
  36. EP4 antagonist

    E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities.
  37. PGF2α analogue

    Tiaprost is a prostaglandin F2α (PGF2α) analogue.
  38. EP1 antagonist

    EP1-antanoist-1 is a EP1 antagonist with a pKi of 7.54 and an pIC50 of 8.5.
  39. EP4 partial agonist

    GSK726701A is a novel prostaglandin E2 receptor 4 (EP4) partial agonist with a pEC50 of 7.4.
  40. EP2 receptor agonist

    Taprenepag isopropyl is a highly selective EP2 receptor agonist.
  41. thromboxane A2 synthase inhibitor

    Terbogrel is an orally available thromboxane A2 receptor antagonist and a thromboxane A2 synthase inhibitor, with both IC50s of about 10 nM.
  42. EP2 receptor antagonist

    TG4-155 is a potent, brain-permeant and selective EP2 receptor antagonist with a Ki of 9.9 nM.
  43. prostaglandin D2 antagonist

    AMG-009 is a potent antagonist of prostaglandin D2, with IC50 of 3 nM and 12 nM for CRTH2 and DP receptors, respectively.
  44. Prostanoid EP2 receptor agonist

    Aganepag is a potent Prostanoid EP2 receptor agonist, with an EC50 of 0.19 nM, and shows no activity at EP4 receptor. Aganepag can be used in the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention.
  45. thromboxane-prostaglandin receptor antagonist

    Terutroban is a thromboxane-prostaglandin receptor antagonist.
  46. CRTH2 antagonist

    MK-7246 is a potent and selective CRTH2 antagonist with a Ki of 2.5??0.5 nM.
  47. DP1/EP2 agonist

    Treprostinil sodium is a potent DP1 and EP2 agonist with EC50 values of 0.6??0.1 and 6.2??1.2 nM, respectively.
  48. prostaglandin EP2 agonist

    AGN 210676 is a selective prostaglandin EP2 agonist extracted from patent US20070203222A1, Compound example 23, has an EC50 of 5 nM.
  49. EP and DP receptor antagonist

    AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP1, EP2, EP3-III, and DP1 receptors.
  50. LTC4 inhibitor

    Nedocromil sodium suppresses the action or formation of multiple mediators, including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2).

Items 1-50 of 55

per page
Set Descending Direction